Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 15/20 | 1.00 |
| ▸ | HTR2B | P41595 | 14/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 11/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | HTR2C | P28335 | 10/20 | 0.68 |
| ▸ | TMIGD3 | P0DMS9 | 5/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | TSPO | P30536 | 1/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24220500 | 0.93 | ADORA3 (1.00) | ADORA1HTR2BADORA3ADORA2ASLC6A2 | |
| SCHEMBL24220484 | 0.84 | ADORA3 (0.72) | ADORA1HTR2BADORA3ADORA2ASLC6A2 | |
| SCHEMBL22087932 | 0.83 | ADORA1 (1.00) | ADORA1HTR2BADORA3ADORA2ASLC6A2 | |
| SCHEMBL24220640 | 0.82 | ADORA3 (1.00) | ADORA1HTR2BADORA3ADORA2ASLC6A2 | |
| SCHEMBL19464941 | 0.81 | HTR2B (1.00) | ADORA1HTR2BADORA3ADORA2ASLC6A2 | |
| SCHEMBL19464934 | 0.81 | HTR2B (1.00) | ADORA1HTR2BADORA3ADORA2ASLC6A2 | |
| SCHEMBL19464867 | 0.81 | HTR2B (1.00) | ADORA1HTR2BADORA3ADORA2ASLC6A2 | |
| SCHEMBL31350144 | 0.78 | HTR2B (1.00) | ADORA1HTR2BADORA3ADORA2AHTR2C | |
| SCHEMBL31350123 | 0.77 | HTR2B (1.00) | ADORA1HTR2BADORA3ADORA2AHTR2C | |
| SCHEMBL3951327 | 0.77 | ADORA3 (1.00) | ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885HTR2B 245/4885ADORA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.